$IMVT insider trading
Over the last 12 months, Immunovant insiders reported 1 buy totaling $350.0M and 39 sales totaling $27.3M across SEC Form 4 filings. 18% of those filings were made under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- $350.0M 1 event
- Sold · 12m
- $27.3M 39 events
- Events · 12m
- 40 Form 4 filings, grouped
- Insiders · 12m
- 11 distinct reporters
- 10b5-1 share
- 18% of events, not dollars
All insider trades
Scroll the table sideways for price, value and marks.
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 28, 2026 | Pande AtulD | ▼ Sale | 1,500 | $43.27 | $65K | -1.3% | plan |
| Aug 20, 2026 | Gloria MelanieChief Operating Officer · O | ▼ Sale | 3,056 | $44.16 | $135K | -1.4% | — |
| Jul 24, 2026 | Pande AtulD | ▼ Sale | 1,500 | $39.8 | $60K | -1.3% | plan |
| Jul 23, 2026 | Girao TiagoChief Financial Officer · O | ▼ Sale | 6,798 | $38.69 | $263K | -2.7% | — |
| Jul 23, 2026 | Stout Jay SChief Technology Officer · O | ▼ Sale | 2,857 | $38.69 | $111K | -1.4% | — |
| Jul 8, 2026 | Gloria MelanieChief Operating Officer · O | ▼ Sale | 2,036 | $39.55 | $81K | -0.9% | 2 tranches |
| Jul 8, 2026 | Van Tuyl ChristopherChief Legal Officer · O | ▼ Sale | 1,206 | $39.55 | $48K | -0.7% | 2 tranches |
| Jul 8, 2026 | Stout Jay SChief Technology Officer · O | ▼ Sale | 3,487 | $39.55 | $138K | -1.6% | 4 tranches |
| Jul 2, 2026 | Venker EricChief Executive Officer · O·D | ▼ Sale | 3,092 | $38.48 | $119K | -1.2% | — |
| Jul 1, 2026 | Venker EricChief Executive Officer · O·D | ▽ Sale to issuer | 86,629 | $38.14 | $3.3M | -25.2% | — |
| Jun 26, 2026 | Gloria MelanieChief Operating Officer · O | ▼ Sale | 17,714 | $38.31 | $679K | -7.3% | 2 tranches |
| Jun 26, 2026 | Stout Jay SChief Technology Officer · O | ▼ Sale | 40,000 | $38.31 | $1.5M | -15.9% | 2 tranches |
| Jun 26, 2026 | Van Tuyl ChristopherChief Legal Officer · O | ▼ Sale | 17,824 | $38.31 | $683K | -9% | 2 tranches |
| Jun 26, 2026 | Girao TiagoChief Financial Officer · O | ▼ Sale | 10,000 | $38.46 | $385K | -3.9% | — |
| Jun 26, 2026 | Pande AtulD | ▼ Sale | 1,500 | $38.01 | $57K | -1.3% | plan |
| Jun 18, 2026 | Van Tuyl ChristopherChief Legal Officer · O | ▼ Sale | 2,634 | $35.39 | $93K | -1.4% | — |
| Jun 15, 2026 | Pande AtulD | ▼ Sale | 1,500 | $34.02 | $51K | -1.3% | plan |
| May 28, 2026 | Fromkin Andrew J.D | ▼ Sale | 210,468 | $33.56 | $7.1M | -73.9% | — |
| May 28, 2026 | Fromkin Andrew J.D | ▼ Sale | 11,483 | $32.64 | $375K | -3.9% | — |
| May 1, 2026 | Susman Robert GrahamD | ▼ Sale | 2,502 | $27.17 | $68K | -6.4% | plan |
| Apr 23, 2026 | Girao TiagoChief Financial Officer · O | ▼ Sale | 25,760 | $29.62 | $763K | -9.4% | — |
| Apr 23, 2026 | Stout Jay SChief Technology Officer · O | ▼ Sale | 2,754 | $29.62 | $82K | -1.1% | — |
| Apr 8, 2026 | Gloria MelanieChief Operating Officer · O | ▼ Sale | 8,722 | $24.83 | $217K | -3.4% | — |
| Apr 8, 2026 | Van Tuyl ChristopherChief Legal Officer · O | ▼ Sale | 5,165 | $24.83 | $128K | -2.7% | — |
| Apr 8, 2026 | Stout Jay SChief Technology Officer · O | ▼ Sale | 10,132 | $24.83 | $252K | -3.8% | 2 tranches |
| Apr 2, 2026 | Venker EricChief Executive Officer · O·D | ▼ Sale | 14,229 | $24.1 | $343K | -42.1% | 2 tranches |
| Apr 1, 2026 | Venker EricChief Executive Officer · O·D | ▽ Sale to issuer | 334,960 | $25.1 | $8.4M | -90.8% | — |
| Mar 18, 2026 | Van Tuyl ChristopherChief Legal Officer · O | ▼ Sale | 2,877 | $24.97 | $72K | -1.9% | — |
| Feb 25, 2026 | Gloria MelanieChief Operating Officer · O | ▼ Sale | 3,238 | $27.85 | $90K | -1.9% | 3 tranches |
| Jan 21, 2026 | Stout Jay SChief Technology Officer · O | ▼ Sale | 1,977 | $26.03 | $51K | -1% | — |
| Jan 7, 2026 | Stout Jay SChief Technology Officer · O | ▼ Sale | 1,203 | $26.53 | $32K | -0.6% | 2 tranches |
| Dec 18, 2025 | Van Tuyl ChristopherChief Legal Officer · O | ▼ Sale | 10,813 | $26.91 | $291K | -6.7% | 2 tranches |
| Dec 12, 2025 | Roivant Sciences Ltd.D·10% | ▲ Buy | 16,666,666 | $21 | $350.0M | +17.2% | — |
| Dec 1, 2025 | Fromkin Andrew J.D | ▼ Sale | 22,249 | $23.25 | $517K | -20.6% | plan · 2 tranches |
| Dec 1, 2025 | Hughes Douglas J.D | ▼ Sale | 15,000 | $23.24 | $349K | -11% | plan · 2 tranches |
| Nov 20, 2025 | Gloria MelanieChief Operating Officer · O | ▼ Sale | 12,626 | $23.62 | $298K | -6.8% | 2 tranches |
| Oct 22, 2025 | Geffner MichaelChief Medical Officer · O | ▼ Sale | 2,595 | $19.03 | $49K | -1.2% | — |
| Oct 22, 2025 | Stout Jay SChief Technology Officer · O | ▼ Sale | 2,520 | $19.03 | $48K | -1.2% | — |
| Oct 8, 2025 | Geffner MichaelChief Medical Officer · O | ▼ Sale | 1,272 | $16.3 | $21K | -0.6% | — |
| Oct 8, 2025 | Stout Jay SChief Technology Officer · O | ▼ Sale | 1,585 | $16.3 | $26K | -0.8% | — |
Every $IMVT filing on this page is one API call away
The same Form 4 data over REST or MCP, already grouped into events with the plan flag and the dollar value read. A free key does 100 calls a day and needs no card. Prefer email? Immunovant filings can reach your inbox instead.
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. This page shows open-market activity: purchases (code P), sales (S) and dispositions back to the issuer (D). Scheduled compensation events such as stock grants and option exercises are also filed on Form 4 but carry no trading signal, so they are not shown and counts here can be lower than the raw EDGAR filing total. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $IMVT feed.